Simplify Logo

Full-Time

Senior – Counsel

Corporate & Transactions

Posted on 6/9/2024

Generation Bio

Generation Bio

51-200 employees

Developing genetic medicines with non-viral delivery

Hardware
Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Category
Legal
Legal & Compliance
Required Skills
Communications
Requirements
  • J.D. and bar admission in good standing in at least one state with eligibility to apply for MA state bar admission
  • Minimum of 4 years of experience as a practicing attorney; at least 3 years of life sciences experience at a law firm or in-house at a public company
  • Ability to assess risk and benefits and convey them clearly
  • Excellent communication, negotiation, and collaboration skills
  • Comfortable working on complex corporate transactional matters and day-to-day vendor agreements
  • Collaborative team player with internal client service focus
  • Strong work ethic and ability to work independently and with discretion
Responsibilities
  • Providing support for corporate and transactional matters, including strategic transactions, collaborations, licensing agreements, securities offerings, financings, investments, and related corporate diligence activities
  • Drafting, reviewing, and negotiating standard contractual provisions with minimal supervision
  • Assisting with SEC filings, including 10-Ks, 10-Qs, periodic reports, Section 16 filings, proxy statements, registrations, and investor relations materials
  • Assisting with general corporate and vendor agreements, MTAs, SOWs, and other day-to-day operational agreements
  • Assisting with corporate governance and compliance with SEC, Nasdaq, and other third-party standards and obligations
  • Coordinating with various departments in contracting matters to support business
  • Possessing an understanding of laws, regulations, and considerations applicable to the development and commercialization of pharmaceutical products

Generation Bio

Company Stage

IPO

Total Funding

$536.4M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

-11%

1 year growth

-23%

2 year growth

-20%
Simplify Jobs

Simplify's Take

What believers are saying

  • The development of iqDNA and ctLNP platforms positions Generation Bio at the forefront of genetic medicine innovation, potentially leading to breakthrough treatments for rare and prevalent diseases.
  • Strategic reorganization and cost-saving measures extend the company's cash runway into the second half of 2027, providing financial stability and continued investment in R&D.
  • High-profile presentations at conferences and collaborations with industry leaders like Moderna enhance the company's visibility and credibility in the biotech sector.

What critics are saying

  • The 40% workforce reduction as part of the strategic reorganization could impact employee morale and productivity.
  • Dependence on successful integration and advancement of iqDNA and ctLNP platforms carries inherent risks if the technologies do not perform as expected in clinical settings.

What makes Generation Bio unique

  • Generation Bio's focus on non-viral genetic medicines using proprietary immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms sets it apart from traditional gene therapy companies.
  • Their scalable capsid-free manufacturing process, utilizing rapid enzymatic synthesis (RES), offers a unique advantage in producing genetic medicines efficiently.
  • The strategic collaboration with Moderna highlights Generation Bio's innovative approach and industry recognition.
INACTIVE